

PRESS RELEASE

Nuclear Medicine Europe announces new leadership for Security of Supply and Therapy Working Groups

01 June 2026

Nuclear Medicine Europe is pleased to announce the election of two new Working Group Chairs, reinforcing the association's commitment to advancing policy, supply security, and patient access to innovative radiopharmaceutical therapies.




Marjolijn Droog elected Chair of the Security of Supply Working Group

Marjolijn Droog has been elected Chair of the Security of Supply Working Group. She brings over a decade of experience in the medical isotope sector, currently serving as Executive Director Medical Isotope Solutions at NRG PALLAS, where she oversees the company's medical isotope business including supply chain optimisation, product development, and business development.

NRG PALLAS operates the High Flux Reactor in Petten, one of the world's largest medical isotope production facilities and a key contributor to the global supply of Molybdenum-99. Marjolijn holds an MBA from Nyenrode Business University in the Netherlands.

Her appointment strengthens Nuclear Medicine Europe's capacity to coordinate on isotope supply security at a time of growing clinical demand for diagnostic and therapeutic radiopharmaceuticals across Europe.



Lada Georgieva elected Chair of the Therapy Working Group

Lada Georgieva has been elected Chair of the Therapy Working Group. Currently serving as Director of Policy and Public Affairs for Region Europe at Novartis, Lada has been shaping strategies to improve system readiness and patient access to innovation, including radioligand therapy. She brings extensive experience in strategic partnerships, high-level negotiations with European institutions, governments, pharmaceutical manufacturers, and

multilateral organisations. Her background spans biotechnology research, strategy consulting, and global health, with a strong track record in managing healthcare emergencies and mobilising resources towards access to innovation.

“With rapid developments in the field, Nuclear Medicine Europe plays a critical role in making nuclear medicine more accessible and in advocating for a sustainable and enabling environment for therapeutic radiopharmaceuticals. I look forward to chairing the Therapy Working Group at a time when collaboration and policy alignment are critical to unlocking the full potential of radioligand therapy for patients across Europe,” said Lada Georgieva.

Both appointments received validation by the Nuclear Medicine Europe Executive Committee in accordance with the association’s statutes.

About Nuclear Medicine Europe

Nuclear Medicine Europe is the industry association representing the full value chain of the nuclear medicine sector across Europe. With over 60 member companies spanning radiopharmaceutical manufacturers, reactor operators, equipment suppliers, and service providers, Nuclear Medicine Europe advocates for a coherent and enabling regulatory environment, supply chain resilience, and equitable patient access to nuclear medicine diagnostics and therapies.

Nuclear Medicine Europe operates through five working groups: Regulatory Affairs & Quality, Therapy, Security of Supply, Transport Experts, and Communications.

For further information: david.crunelle@nmeu.org | www.nmeu.org